Surgery for stage IIIA-N2 non-small cell lung cancer: the jury is still out! | Zendy

Lawek Berzenji | Zendy; Paul A. J. Beckers | Zendy; Paul Van Schil | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Surgery for stage IIIA-N2 non-small cell lung cancer: the jury is still out!

Author(s) -

Lawek Berzenji,

Paul A. J. Beckers,

Paul Van Schil

Publication year - 2019

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2019.04.36

Subject(s) - medicine , stage (stratigraphy) , lung cancer , concomitant , chemoradiotherapy , randomized controlled trial , oncology , clinical trial , surgery , cancer , paleontology , biology

Stage IIIA-N2 non-small cell lung cancer (NSCLC) comprises a very heterogeneous group of locally advanced tumors for which optimal treatment strategies remain highly controversial although results of large randomized controlled trials are available (1). In general, recommended treatment for pathologically proven, clinical stage IIIA-N2 NSCLC consists of concomitant chemoradiotherapy (CRT) (2). However, the prognosis for this patient group remains poor (3). The role of surgery in the multimodality setting is intensively debated and different treatment recommendations have been proposed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research